2-(2,6-Dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)oxy)isoindoline-1,3-dione

Target: This compound binds cereblon and functions as an IMiD-derived E3 ligand.

Binding site: It engages the thalidomide-binding pocket within the CRBN substrate receptor.

Mechanism of action: 2-(2,6-Dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)oxy)isoindoline-1,3-dione is best described as a cereblon-binding building block rather than a complete target-degrading PROTAC. Its glutarimide-phthalimide scaffold is structurally related to thalidomide-class CRBN ligands, while the terminal hydroxyheptyloxy substituent provides a functional handle for linker attachment. In PROTAC design, this compound can serve as the E3 ligase recruitment module, enabling construction of bifunctional degraders when coupled to a target-binding ligand. It supports structure-activity exploration of linker length, exit-vector geometry, CRBN engagement, and degradation-competent ternary complex formation.

• PROTAC-Mediated Protein Degradation: This compound serves as a bifunctional molecule designed to facilitate the selective degradation of target proteins through the ubiquitin-proteasome system. By linking a ligand for the target protein with an E3 ligase ligand, it enables the recruitment of the ubiquitin machinery, leading to proteasomal degradation and subsequent reduction of the target protein levels.

• Targeted Degradation in Cancer Research: Utilizing this PROTAC, researchers can explore novel therapeutic strategies to degrade oncogenic proteins that are traditionally considered "undruggable." This approach allows for the investigation of the compound's ability to selectively and efficiently degrade proteins involved in cancer cell proliferation and survival, providing insights into potential treatment pathways.

• Investigating Protein-Protein Interactions: The compound facilitates the study of protein-protein interactions by enabling the targeted degradation of specific proteins, thereby allowing researchers to dissect complex signaling pathways. This application is particularly valuable in understanding the dynamic roles of transient protein interactions in various cellular processes.

• Advancing Drug Discovery: By employing this PROTAC, scientists can accelerate drug discovery efforts focused on targeted protein degradation. The compound's ability to induce specific degradation of disease-related proteins provides a powerful tool for identifying and validating new drug targets, ultimately contributing to the development of innovative therapeutic agents.